Drug Week

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Antiviral Therapy

Entecavir prevents viral persistence after duck hepatitis B infection

According to recent research published in the Journal of Virology, "entecavir (ETV), a potent inhibitor of the hepadnaviral polymerases, prevented the development of persistent infection when administered in the early stages of duck hepatitis B virus (DHBV) infection. In a preliminary experiment, ETV treatment commenced 24 h before infection showed no significant advantage over simultaneous ETV treatment and infection."

"In two further experiments 14-day-old ducks were inoculated with DHBV-positive serum containing 10⁴, 10⁶, 10⁸, or 5 X...

• View Other Issues of Drug Week
  
• View Other NewsRx Publications